Heterogeneous BCR-ABL1 signal patterns identified by fluorescence in situ hybridization are associated with leukemic clonal evolution and poorer prognosis in BCR-ABL1 positive leukemia

Table 2 The clinical features of CML-BP and BCR-ABL1 positive ALL patients

Characteristics	CML-BP	BCR-ABL1⁺ ALL	P value
Number of patients	17	52
Median Age, y (Range)	42.9 (15–70)	39.0 (13–76)	0.306
Male/Female, %	52.9/47.1	57.7/42.3	0.631
Leukocyte count, 10⁹/L (range)	97.2 (1.0–303)	57.4 (1.1–308)	0.131
Hemoglobin, g/L (range)	82.5 (48–132)	87.3 (38–149)	0.630
Thrombocyte count, 10⁹/L (range)	268.5 (13–2488)	43.0 (3–230)	0.000
LDH, U/L (range)	1059 (98–5490)	836 (156–5353)	0.526
Cytogenetic abnormalities, %			0.684
t (9;22)	4/17 (23.5%)	11/52 (21.2%)
ACAs	5/17 (29.4%)	11/52 (21.2%)
No split phase	8/17 (47.1%)	30/52 (57.7%)
BCR-ABL1 FISH			0.068
Complex signal pattern	9/17 (52.9%)	16/52 (30.8%)
Typical single pattern	5/17 (29.4%)	28/52 (53.8%)
Atypical single pattern	3/17 (17.6%)	8/52 (15.4%)
Splenomegaly			0.000
Normal-mild	8/17 (47.1%)	51/52 (98.0%)
Moderate- severe	9/17 (52.9%)	1/52 (2.0%)

Abbreviations: CML-BP = chronic myeloid leukemia-blast phase, ALL = acute lymphoblastic leukemia, LDH = Lactate dehydrogenase, ACAs = additional cytogenetic abnormalities, Complex signal pattern = two or more types of BCR-ABL signal patterns, Single pattern = single 1R1G2F fusion signal or other single BCR-ABL fusion signals other than 1R1G2F. Mild splenomegaly: <3 cm under the ribs; Moderate splenomegaly: 3 ~ 6 cm under the ribs; Severe splenomegaly: >6 cm under the ribs

ISSN: 1471-2407